-+ 0.00%
-+ 0.00%
-+ 0.00%

CDT Equity partners with QIMA Life Sciences to study tapinarof combination therapies in psoriasis and vitiligo

PUBT·09/18/2026 10:30:27
Listen to the news
CDT Equity partners with QIMA Life Sciences to study tapinarof combination therapies in psoriasis and vitiligo
  • CDT Equity entered a partnership with QIMA Life Sciences to evaluate novel tapinarof combination therapies in autoimmune skin diseases.
  • Initial work targets plaque psoriasis, using human psoriatic skin to support development of a second-generation tapinarof topical with improved efficacy.
  • Studies will also assess tapinarof combinations in vitiligo, which affects about 0.5%-2.0% of the global population.
  • Vitiligo drug market estimated at about US$2.6 billion in 2025, projected to reach US$6.6 billion by 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CDT Equity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180630PRIMZONEFULLFEED9829456) on September 18, 2026, and is solely responsible for the information contained therein.